Clinical-stage biotechnology company developing cell therapies for cancer and autoimmune diseases.
Cartesian Therapeutics, Inc. is a pioneering clinical-stage biotechnology company specializing in mRNA cell therapies tailored for the treatment of autoimmune diseases. Headquartered in Gaithersburg, Maryland, the company is dedicated to advancing innovative treatments that harness the power of RNA engineering.
At the forefront of Cartesian Therapeutics' portfolio is Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy. Currently in Phase 2b clinical development, Descartes-08 is targeted for treating generalized myasthenia gravis and is also being evaluated in systemic lupus erythematosus, as well as myeloma autoimmune basket trials aimed at addressing a spectrum of autoimmune diseases.
In addition to Descartes-08, Cartesian Therapeutics is developing Descartes-15, designed to target autoimmune diseases and myeloma. The company's pipeline also includes Descartes-33, currently in preclinical stages, intended for the treatment of autoimmune diseases, further expanding its therapeutic capabilities.
Cartesian Therapeutics collaborates with leading experts in autoimmune diseases and mRNA technology to drive its innovative therapies forward. With a commitment to scientific excellence and patient-focused innovation, the company continues to push boundaries in biotechnology, aiming to deliver transformative treatments to patients in need worldwide.